Loading...

OptiBiotix Health

DB:OB3
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OB3
DB
£70M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Optibiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The last earnings update was 234 days ago. More info.


Add to Portfolio Compare Print
OB3 Share Price and Events
7 Day Returns
-2.2%
DB:OB3
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-
DB:OB3
-10.2%
DE Biotechs
-6%
DE Market
OB3 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
OptiBiotix Health (OB3) -2.2% 0.1% -7% - - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • No trading data on OB3.
  • No trading data on OB3.
Price Volatility
OB3
Industry
5yr Volatility vs Market
Related Companies

OB3 Value

 Is OptiBiotix Health undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for OptiBiotix Health. This is due to cash flow or dividend data being unavailable. The share price is €0.904.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for OptiBiotix Health's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are OptiBiotix Health's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:OB3 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-05-31) in GBP £-0.03
AIM:OPTI Share Price ** AIM (2019-04-18) in GBP £0.82
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of OptiBiotix Health.

DB:OB3 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:OPTI Share Price ÷ EPS (both in GBP)

= 0.82 ÷ -0.03

-27.98x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OptiBiotix Health is loss making, we can't compare its value to the Europe Biotechs industry average.
  • OptiBiotix Health is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does OptiBiotix Health's expected growth come at a high price?
Raw Data
DB:OB3 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -27.98x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for OptiBiotix Health, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on OptiBiotix Health's assets?
Raw Data
DB:OB3 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-05-31) in GBP £0.10
AIM:OPTI Share Price * AIM (2019-04-18) in GBP £0.82
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:OB3 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:OPTI Share Price ÷ Book Value per Share (both in GBP)

= 0.82 ÷ 0.10

8.5x

* Primary Listing of OptiBiotix Health.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OptiBiotix Health is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess OptiBiotix Health's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. OptiBiotix Health has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

OB3 Future Performance

 How is OptiBiotix Health expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OptiBiotix Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is OptiBiotix Health expected to grow at an attractive rate?
  • Unable to compare OptiBiotix Health's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare OptiBiotix Health's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare OptiBiotix Health's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:OB3 Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:OB3 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (10 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:OB3 Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:OB3 Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2018-05-31 0 -2 -2
2018-02-28 0 -2 0
2017-11-30 0 -2 2
2017-08-31 0 -2 2
2017-05-31 0 -1 2
2017-02-28 0 -1 1
2016-11-30 0 -1 -1
2016-08-31 0 -1 -1
2016-05-31 0 -1 -1
2016-02-29 0 -1 -1
2015-11-30 0 -1 -1
2015-08-31 0 -1 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if OptiBiotix Health is high growth as no earnings estimate data is available.
  • Unable to determine if OptiBiotix Health is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:OB3 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (10 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from OptiBiotix Health Company Filings, last reported 10 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:OB3 Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:OB3 Past Financials Data
Date (Data in GBP Millions) EPS *
2018-05-31 -0.03
2018-02-28 0.00
2017-11-30 0.02
2017-08-31 0.03
2017-05-31 0.03
2017-02-28 0.01
2016-11-30 -0.02
2016-08-31 -0.02
2016-05-31 -0.02
2016-02-29 -0.02
2015-11-30 -0.02
2015-08-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if OptiBiotix Health will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine OptiBiotix Health's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. OptiBiotix Health's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. OptiBiotix Health's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess OptiBiotix Health's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
OptiBiotix Health has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

OB3 Past Performance

  How has OptiBiotix Health performed over the past 5 years?

  • OptiBiotix Health's last earnings update was 234 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare OptiBiotix Health's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • OptiBiotix Health does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare OptiBiotix Health's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare OptiBiotix Health's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
OptiBiotix Health's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from OptiBiotix Health Company Filings, last reported 10 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:OB3 Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-05-31 0.20 -2.30 1.53 0.30
2018-02-28 0.19 -0.20 1.62 0.30
2017-11-30 0.19 1.91 1.70 0.30
2017-08-31 0.23 2.17 1.58 0.31
2017-05-31 0.27 2.44 1.46 0.31
2017-02-28 0.28 0.57 1.35 0.31
2016-11-30 0.29 -1.30 1.24 0.31
2016-08-31 0.20 -1.34 1.29 0.27
2016-05-31 0.12 -1.38 1.34 0.23
2016-02-29 0.07 -1.33 1.20 0.23
2015-11-30 0.03 -1.28 1.05 0.23
2015-08-31 0.01 -1.27 0.96 0.14
2015-05-31 -1.27 0.87 0.06
2015-02-28 -1.04 0.64 0.06
2014-11-30 -0.81 0.41 0.06
2014-05-31 0.36 0.15
2014-02-28 -0.64 0.20
2013-11-30 -1.63 0.26
2013-01-31 0.25 -1.29 0.31
2012-10-31 0.21 -1.47 0.49
2012-07-31 0.16 -1.65 0.66

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if OptiBiotix Health has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if OptiBiotix Health has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if OptiBiotix Health improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess OptiBiotix Health's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
OptiBiotix Health has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

OB3 Health

 How is OptiBiotix Health's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up OptiBiotix Health's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • OptiBiotix Health is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • OptiBiotix Health's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of OptiBiotix Health's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • OptiBiotix Health has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from OptiBiotix Health Company Filings, last reported 10 months ago.

DB:OB3 Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2018-05-31 7.60 0.00 1.80
2018-02-28 7.60 0.00 1.80
2017-11-30 7.05 0.00 1.25
2017-08-31 7.05 0.00 1.25
2017-05-31 8.14 0.00 1.92
2017-02-28 8.14 0.00 1.92
2016-11-30 5.00 0.00 3.12
2016-08-31 5.00 0.00 3.12
2016-05-31 5.63 0.00 3.56
2016-02-29 5.63 0.00 3.56
2015-11-30 3.82 0.00 2.04
2015-08-31 3.82 0.00 2.04
2015-05-31 4.35 0.00 2.47
2015-02-28 4.35 0.00 2.47
2014-11-30 4.65 0.00 2.87
2014-05-31 0.11 0.00 0.11
2014-02-28 0.11 0.00 0.11
2013-11-30 0.10 0.00 0.00
2013-01-31 0.35 0.02 0.01
2012-10-31 0.35 0.02 0.01
2012-07-31 0.44 0.08 0.03
  • OptiBiotix Health has no debt.
  • OptiBiotix Health has no debt compared to 5 years ago when it was 5.5%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • OptiBiotix Health has less than a year of cash runway based on current free cash flow.
  • OptiBiotix Health has less than a year of cash runway if free cash flow continues to grow at historical rates of 18.1% each year.
X
Financial health checks
We assess OptiBiotix Health's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. OptiBiotix Health has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

OB3 Dividends

 What is OptiBiotix Health's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from OptiBiotix Health dividends.
If you bought €2,000 of OptiBiotix Health shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate OptiBiotix Health's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate OptiBiotix Health's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:OB3 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:OB3 Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as OptiBiotix Health has not reported any payouts.
  • Unable to verify if OptiBiotix Health's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of OptiBiotix Health's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as OptiBiotix Health has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess OptiBiotix Health's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can OptiBiotix Health afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. OptiBiotix Health has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

OB3 Management

 What is the CEO of OptiBiotix Health's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Stephen O'Hara
COMPENSATION £200,000
CEO Bio

Mr. Stephen Patrick O'Hara Founded OptiBiotix Health plc in March 2012 and serves as its Chief Executive. He also serves as the Board Director of ProBiotix Health Limited. Mr. O'Hara served as the Chief Executive Officer at SkinBioTherapeutics PLC since June 10, 2015. Mr. O'Hara held senior executive and non-executive roles with SME's, the NH and 3M, where he was Director of Microbiology. He has been an Executive Director at OptiBiotix Health plc since August 5, 2014. He has published over 45 scientific and business articles, a number of patents, written chapters for three books, acted as editorial referee for numerous journals and chaired US and European Scientific Advisory Committees. He has a track record of building business cases for investment and successful company exit. He serves as a Non-Executive Director of SkinBioTherapeutics PLC since March 2015.

CEO Compensation
  • Stephen's compensation has been consistent with company performance over the past year.
  • Stephen's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the OptiBiotix Health management team in years:

0.9
Average Tenure
52
Average Age
  • The average tenure for the OptiBiotix Health management team is less than 2 years, this suggests a new team.
Management Team

Stephen O'Hara

TITLE
Founder
COMPENSATION
£200K

Mark Collingbourne

TITLE
Chief Financial Officer
AGE
52

Kevin Newman

TITLE
Corporate Development Director

Christina Wood

TITLE
Sales & Marketing Director and Director
AGE
58
TENURE
2.3 yrs

Steven Riley

TITLE
Head of Online Sales & Marketing
TENURE
0.9 yrs

Fred Narbel

TITLE
Managing Director of Prebiotics Division
TENURE
0.1 yrs

Sofia Kolyda

TITLE
Director of Research & Development and Director
AGE
45
Board of Directors Tenure

Average tenure and age of the OptiBiotix Health board of directors in years:

2.7
Average Tenure
59
Average Age
  • The average tenure for the OptiBiotix Health board of directors is less than 3 years, this suggests a new board.
Board of Directors

Richard Colin Davidson

TITLE
Non-Executive Chairman
AGE
67
TENURE
1.3 yrs

Stephen O'Hara

TITLE
Founder
COMPENSATION
£200K
TENURE
4.7 yrs

Christina Wood

TITLE
Sales & Marketing Director and Director
AGE
58
TENURE
2.1 yrs

Sofia Kolyda

TITLE
Director of Research & Development and Director
AGE
45
TENURE
0.8 yrs

Jan Peter Wennström

TITLE
Non-Executive Director
COMPENSATION
£11K
AGE
60
TENURE
3.4 yrs

Gareth Barker

TITLE
Non-Executive Director
COMPENSATION
£23K
AGE
52
TENURE
4.4 yrs

Tim Spector

TITLE
Member of Scientific Advisory Group
TENURE
3.3 yrs

Sean Christie

TITLE
Non-Executive Director
AGE
61
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess OptiBiotix Health's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. OptiBiotix Health has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

OB3 News

Simply Wall St News

OB3 Company Info

Description

Optibiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; CholBiome, an ingredient for use in a range of functional food products and supplements in consumer and pharmaceutical health care; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galacto oligosaccharide that are used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; and Sweetbiotix, a sweetener for use in food products and beverages. The company’s products prevents and manages chronic lifestyle diseases, including obesity, hypercholesterolemia and lipid profiles, and diabetes. Optibiotix Health Plc was founded in 2012 and is headquartered in York, the United Kingdom.

Details
Name: OptiBiotix Health Plc
OB3
Exchange: DB
Founded: 2012
£80,492,163
85,440,551
Website: http://www.optibiotix.com
Address: OptiBiotix Health Plc
Innovation Centre,
Innovation Way,
York,
North Yorkshire, YO10 5DG,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM OPTI Ordinary Shares London Stock Exchange AIM Market GB GBP 05. Aug 2014
OTCPK OPBX.F SHS Pink Sheets LLC US USD 19. Oct 2015
AIM OPTI ORD GBP0.02 London Stock Exchange AIM Market GB GBP 15. Nov 2016
DB OB3 ORD GBP0.02 Deutsche Boerse AG DE EUR 15. Nov 2016
BST OB3 ORD GBP0.02 Boerse-Stuttgart DE EUR 15. Nov 2016
Number of employees
Current staff
Staff numbers
8
OptiBiotix Health employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:57
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2017/04/25
Last earnings filing: 2018/08/30
Last earnings reported: 2018/05/31
Last annual earnings reported: 2017/11/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.